CIRBP

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funders: National Cancer Institute and 7 more
4 of 4 findings with company ties

Model organisms1
Cells1

Effects

DNA repair

upin human cells2

2 studies

CIRBP increases DNA repair in human cells.
“Bowhead whale CIRBP enhanced both non-homologous end joining and homologous recombination repair in human cells”
Cellsbowhead whale CIRBP; non-homologous end joining and homologous recombination
Evidence for improved DNA repair in the long-lived bowhead whale
Nature29 Oct 2025
CIRBP increases DNA repair in human cells.
“CIRBP and its downstream protein RPA2, also present at high levels in bowhead cells, increase the efficiency and fidelity of DNA repair in human cells”
Cellsin human cells
DNA repair and anti-cancer mechanisms in the long-lived bowhead whale
bioRxiv : the preprint server for biology5 Nov 2024Preprint